Skip to Main Content

Ketamine for the Treatment of Depression in Parkinson's Disease

Conditions

Mental Health & Behavioral Research | Alzheimer's Disease

What is the purpose of this trial?

The main purpose of this study is to examine the efficacy, safety and mechanistic underpinnings of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD.

A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.

  • Trial with
    Michael J. Fox Foundation
  • Start Date
    11/23/2021
  • End Date
    08/31/2024

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    12/17/2021
  • Study HIC
    #2000030394